#Taiwan #Taipei #HanchorBio #HCB101 #CancerTreatment

HanchorBio's Groundbreaking Presentations at the SITC 2025

HanchorBio Inc., a key player in next-generation immunotherapy development, recently showcased two exciting late-breaking abstracts at the Society for Immunotherapy of Cancer (SITC) 2025. This annual meeting, held in National Harbor, Maryland from November 5-9, gathered leaders in cancer therapy to discuss innovative approaches in the field. The abstracts focused on HCB101, HanchorBio's flagship product, which has shown significant promise in combating advanced cancers that typically resist conventional immunotherapies.

Pioneering HCB101: A Class Apart in Immunotherapy

HCB101 represents a new generation of SIRPα-CD47 fusion proteins, designed specifically to enhance safety while maintaining efficacy. HanchorBio has engineered HCB101 to address the limitations of earlier CD47-targeting treatments which have struggled with safety and effectiveness. The company's innovative approach ensures that patients can receive treatment without the severe side effects that have impacted past therapies. Moreover, the results from the latest studies underscore HCB101's potential for both monotherapy and in combination with standard care regimens.

Key Findings from the Studies Presented:

1. HCB101-101 Monotherapy Study (NCT05892718): This ongoing Phase 1a trial has shown no dose-limiting toxicities at doses reaching 24 mg/kg. Early results point to a receptor occupancy of over 99% at doses of 5 mg/kg or higher. Patients with head and neck squamous cell carcinoma (HNSCC) and marginal zone lymphoma (MZL) exhibit stable disease with progression-free survival lasting up to 32 weeks.

2. HCB101-201 Combination Therapy Study (NCT06771622): This Phase 1b/2a investigation into the effectiveness of HCB101 alongside standard treatments has yielded incredible results, particularly in second-line gastric cancer patients, where a 100% confirmed partial response rate was observed in evaluable patients. Furthermore, researchers noted remarkable tumor shrinkage, surpassing expectations established in previous benchmarks.

Impact on Treatment Paradigms

Scott Liu, Ph.D., the founder and CEO of HanchorBio, expressed his optimism regarding the results: "The acceptance of these late-breaking abstracts reinforces the unique potential of HCB101 as a ‘best-in-class’ option. It not only addresses the safety concerns of traditional anti-CD47 therapies but also demonstrates superior efficacy in notoriously difficult-to-treat cancers. Our combination therapy illustrated an impressive response rate that could redefine treatment standards for advanced gastric cancer."

Dr. Fangling Ning from Binzhou Medical University contributes valuable insight as an investigator in the study, emphasizing that HCB101 uniquely avoids issues of cytopenia commonly seen in earlier treatments while effectively targeting CD47 on tumor cells. The results affirm the potential significance of HCB101, particularly for patients previously lacking viable treatment options.

Conclusion

HanchorBio is positioned at the forefront of therapeutic innovation with HCB101’s presentation at SITC 2025. The promising results not only pave the way for its clinical application across a broader range of conditions but also signify a hopeful advance for patients facing advanced cancers. As they continue to explore this fascinating development, HanchorBio remains dedicated to battling the challenges of cancer treatment through cutting-edge strategies and technologies, aiming to deliver transformative options for oncological patients around the world.

For more information and ongoing updates about HCB101 and other HanchorBio ventures, please visit HanchorBio’s website.